CVS GROUP PLC — Board/Management Information 2026

Apr 21, 2026

National Storage Mechanism | Additional information

RNS Number : 3465B

CVS Group plc

21 April 2026

For Immediate Release                                                                                                                                              21 April 2026

CVS Group plc

("CVS", the "Company" or the "Group")

Non-Executive Director Appointment

CVS, the UK listed veterinary group and a leading provider of veterinary services, is pleased to announce the appointment of Laura Hagan as an Independent Non-Executive Director with effect from 1 May 2026.

Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology.  Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board.

From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee.

Commenting on the appointment of Laura, CVS Chair David Wilton said:

"On behalf of the board, I am delighted to welcome Laura to CVS and I look forward to working with her. Laura's appointment, following that of Helen Keays and Jane Bednall announced on 25 March 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion."

The Company confirms that there is no further information about Laura Hagan requiring disclosure under paragraphs 6.4.8R (1) to (6) of the FCA UK Listing Rules.

Contacts

CVS Group plc                                                                                           via Camarco

Richard Fairman, Chief Executive Officer

Scott Morrison, Group Legal Counsel and Company Secretary

Camarco (Financial PR)                                                                                            

Ginny Pulbrook                                                                                          [email protected]

Tilly Butcher                                                                                              +44 (0)20 3757 4980

Letaba Rimell                                                                           

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAPPUCCCUPQGGG